The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | ZUMA-1: 3-year follow-up on axi-cel in LBCL patients
Frederick Locke, MD, Moffitt Cancer Center, Tampa, FL, shares the findings of long-term follow-up results from the ZUMA-1 Phase I/II trial (NCT02348216) of axicabtagene ciloleucel (axi-cel) in refractory large B-cell lymphoma (LBCL). Axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, is approved for use in relapsed/refractory LBCL and has shown high durable response rates in the previously reported 2-year analysis of ZUMA-1. This extended analysis, with a median follow up of 39 months, is concordant with the 2-year findings of durable responses, with a median overall survival (OS) of 25.8 months. When flow cytometry was used to characterize patient B-cells, nearly all patients with ongoing responses at 3-years showed recovery of polyclonal B-cells. It was also observed that over half the ongoing responders had minimal levels of CAR T-cells and a normalized B-cell compartment, suggesting CAR T-cell persistence is not required for extended remission. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
